Heather Davis
17Patents
9h-index
57Co-inventors
71Inventor score
Filing activity: Jul 26, 2004 → Apr 23, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9637453B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | Chemistry; Metallurgy | 50 | Active |
| US9630922B2 | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors | Chemistry; Metallurgy | 49 | Active |
| US9428495B2 | Selectively substituted quinoline compounds | Chemistry; Metallurgy | 33 | Active |
| US10214500B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 20 | Active |
| US10442776B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 15 | Active |
| US10421732B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 15 | Active |
| US10464910B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 12 | Active |
| US10464909B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 12 | Active |
| US10457652B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 12 | Active |
| US7666875B2 | Hydantoin compounds | Human Necessities | 9 | Expired |
| US7202363B2 | Thienopyridine and furopyridine kinase inhibitors | Emerging Cross-Sectional Technologies | 6 | Expired |
| US10988450B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 6 | Active |
| US7737160B2 | Thienopyridine and furopyridine kinase inhibitors | Emerging Cross-Sectional Technologies | 2 | Active |
| US11891365B2 | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US8273736B2 | Thienopyridine and furopyridine kinase inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US9567339B2 | Primary carboxamides as BTK inhibitors | Chemistry; Metallurgy | 0 | Active |
| USRE47193E1 | Selectively substituted quinoline compounds | General | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.